Objective: Uveitis has been increasingly recognised as a side effect of rifabutin regimens in the prophylaxis and treatment of Mycobacterium avium intracellulare (MAI) 
Introduction
Many recent advances in the management of HIV disease stem from improved treatment and prophylaxis of opportunist infections.' Mycobacterium avium intracellulare (MAI) is one of the commonest causes of secondary opportunistic infections in AIDS, often dominating its later stages. Recognition of the associated morbidity and the development of more effective drugs against this organism have improved the survival of patients with MAI bacteraemia. 2 3 Rifabutin, a semi-synthetic derivative of rifampicin-S, is a broad spectrum antibiotic which is particularly active against mycobacterial species. It has several similar side effects to rifampicin including nausea, vomiting, hepatotoxicity and the risk of drug interactions but apparently with lower frequency. A reversible syndrome of arthralgia and arthritis has been described and in one dose-ranging study two cases of uveitis at high doses were also noted.4 A recent Canadian multicentre trial using rifabutin 600 mg in combination with clarithromycin 2 g daily and ethambutol 15 Discussion Uveitis in HIV disease has been described in the context of opportunist infections (Mycobacterium tuberculosis, syphilis, herpes zoster) and possibly secondary to HIV itself." 12 Uveitis associated with rifabutin was initially noted at doses greater than 1500 mg.4 It was later shown to occur frequently at therapeutic doses of 600 mg in combination with clarithromycin and ethambutol.'3'4 A substantially lower incidence of uveitis has been noted where rifabutin at 300 mg has been used as monotherapy in primary MAI infection prophylaxis. Although the data do not completely exclude the possibility of a new intraocular pathogen we are confident that rifabutin was the most likely cause of uveitis in this series. There was a cluster of nine cases of uveitis in a three month period in patients on therapy for MAI infection following a change in the unit's protocol for treatment of this infection. We thank Dr R Wild and Pharmacia Ltd for the supply of information and for useful discussions.
